How is Astellas addressing Xtandi patent loss while Moderna’s flu shot nears FDA review?

Astellas plans about $1.3 billion in annual savings from 2026 to 2030 to offset revenue risks from expiring Xtandi patents, possibly funding a large‑scale acquisition. Meanwhile, the FDA will review Moderna’s mRNA flu vaccine, mFlusia, for adults 50 and older, a test of post‑pandemic confidence in mRNA technology.